company background image
TCRX

TScan Therapeutics NasdaqGM:TCRX Stock Report

Last Price

US$2.21

Market Cap

US$53.2m

7D

-4.3%

1Y

-66.7%

Updated

05 Dec, 2022

Data

Company Financials +
TCRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

TCRX Stock Overview

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.

TScan Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for TScan Therapeutics
Historical stock prices
Current Share PriceUS$2.21
52 Week HighUS$6.96
52 Week LowUS$1.60
Beta0
1 Month Change-14.01%
3 Month Change-35.47%
1 Year Change-66.67%
3 Year Changen/a
5 Year Changen/a
Change since IPO-78.95%

Recent News & Updates

TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M

Aug 10

TScan Therapeutics appoints Debora Barton as Chief Medical Officer

Jul 07

Recent updates

Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

May 22
Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

Jan 17
Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

Oct 18
We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

Shareholder Returns

TCRXUS BiotechsUS Market
7D-4.3%3.2%1.1%
1Y-66.7%-6.5%-17.6%

Return vs Industry: TCRX underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: TCRX underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is TCRX's price volatile compared to industry and market?
TCRX volatility
TCRX Average Weekly Movement13.5%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: TCRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: TCRX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2018129David Southwellhttps://www.tscan.com

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2.

TScan Therapeutics, Inc. Fundamentals Summary

How do TScan Therapeutics's earnings and revenue compare to its market cap?
TCRX fundamental statistics
Market CapUS$53.22m
Earnings (TTM)-US$61.70m
Revenue (TTM)US$13.29m

4.0x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TCRX income statement (TTM)
RevenueUS$13.29m
Cost of RevenueUS$56.82m
Gross Profit-US$43.53m
Other ExpensesUS$18.17m
Earnings-US$61.70m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.56
Gross Margin-327.43%
Net Profit Margin-464.10%
Debt/Equity Ratio24.9%

How did TCRX perform over the long term?

See historical performance and comparison